Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc.（CRVS）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · CRVS · 截至 2026年6月8日
活动摘要
买入笔数
2
P-Purchase only
卖出笔数
2
近12个月
买卖比
1.00
Buy/Sell (by trades)
整体情绪
Corvus Pharmaceuticals, Inc.内部人在过去近12个月买卖活动混合。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
CRVS 季度内部人买卖趋势
CRVS 内幕交易卖出 · CRVS 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · CRVS CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
CRVS 高管卖出股份 · CRVS 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 18, 2026 | MILLER RICHARD A MD President and CEO · Director | Purchase | 1,932 | $23K | Form 4 |
| May 18, 2026 | MILLER RICHARD A MD President and CEO · Director | Purchase | 5,000 | $60K | Form 4 |
| Jan 28, 2026 | Thompson Peter A. Director | Option | 15,000 | $32K | Form 4 |
| Jan 28, 2026 | Thompson Peter A. Director | Option | 15,000 | $25K | Form 4 |
| Jan 28, 2026 | Thompson Peter A. Director | Option | 15,000 | $37K | Form 4 |
| Jan 28, 2026 | Thompson Peter A. Director | Option | 15,000 | $14K | Form 4 |
| Jan 28, 2026 | Thompson Peter A. Director | Option | 15,000 | $15K | Form 4 |
| Jan 28, 2026 | Thompson Peter A. Director | Option | 15,000 | $39K | Form 4 |
| Jan 28, 2026 | Thompson Peter A. Director | Option | 15,000 | $41K | Form 4 |
| Jan 28, 2026 | Thompson Peter A. Director | Option | 15,000 | $49K | Form 4 |
| Jan 28, 2026 | Thompson Peter A. Director | Option | 15,000 | $30K | Form 4 |
| Jan 28, 2026 | Thompson Peter A. Director | Option | 15,000 | $54K | Form 4 |
| Jan 28, 2026 | Thompson Peter A. Director | Option | 15,000 | $188K | Form 4 |
| Jan 28, 2026 | Thompson Peter A. Director | Option | 15,000 | $146K | Form 4 |
| Jan 28, 2026 | Thompson Peter A. Director | Option | 30,000 | $450K | Form 4 |
| Jun 27, 2025 | ORBIMED ADVISORS LLC Director | Other | 1,397,684 | $4.89M⚡ | Form 4 |
| Jun 27, 2025 | ORBIMED ADVISORS LLC Director | Sale | 1,176,332 | $4.89M⚡ | Form 4 |
| Jun 27, 2025 | Thompson Peter A. Director | Other | 1,397,684 | $4.89M⚡ | Form 4 |
| Jun 27, 2025 | Thompson Peter A. Director | Sale | 1,176,332 | $4.89M⚡ | Form 4 |
| Jun 4, 2025 | Jones William Benton See Remarks | Option | 19,357 | $68K | Form 4 |
| May 7, 2025 | MILLER RICHARD A MD President and CEO · Director | Option | 559,073 | $1.96M⚡ | Form 4 |
| May 10, 2024 | MILLER RICHARD A MD President and CEO · Director | Gift | 302,016 | — | Form 4 |
| May 6, 2024 | Jones William Benton See Remarks | Purchase | 20,000 | $35K | Form 4 |
| May 6, 2024 | MILLER RICHARD A MD President and CEO · Director | Purchase | 577,634 | $1000K | Form 4 |
| May 15, 2023 | Grais Linda Director | Purchase | 10,000 | $25K | Form 4 |
MILLER RICHARD A MD
President and CEO · Director
日期
May 18
股数
1,932
均价
$12.01
总金额
$23K
MILLER RICHARD A MD
President and CEO · Director
日期
May 18
股数
5,000
均价
$12.05
总金额
$60K
MILLER RICHARD A MD
President and CEO · Director
日期
May 7
股数
559,073
均价
$3.50
总金额
$1.96M ⚡
MILLER RICHARD A MD
President and CEO · Director
日期
May 6
股数
577,634
均价
$1.73
总金额
$1000K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 CRVS 内幕交易
CRVS 内幕交易
Corvus Pharmaceuticals, Inc.（CRVS）内幕交易数据来源于公司内部人（包括Thompson Peter A. (Director), MILLER RICHARD A MD (President and CEO · Director), ORBIMED ADVISORS LLC (Director)）提交的SEC Form 4申报文件。过去12个月内，3位内部人向SEC提交了交易申报。CRVS内部人近期买卖活动混合，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Corvus Pharmaceuticals, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
CRVS 内幕交易 · 5个问题Corvus Pharmaceuticals, Inc.（CRVS）的内部人包括高管和董事，如Thompson Peter A. (Director), MILLER RICHARD A MD (President and CEO · Director), ORBIMED ADVISORS LLC (Director)等。过去12个月内，3位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026